Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-DUR vs MINITRAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Prophylaxis and treatment of angina pectoris due to coronary artery disease,Heart failure (IV formulation),Hypertensive crisis (IV formulation),Anal fissures (topical ointment)
Acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack),Chronic angina (off-label: long-term prophylaxis),Heart failure associated with acute myocardial infarction (off-label)
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Metabolized by glutathione S-transferases (GSTs) in the liver and erythrocytes, producing glycerol dinitrate and nitrite ions.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
~60% (mainly to albumin).
Approximately 60% bound to plasma proteins (albumin).
~3 L/kg (extensive tissue distribution).
Vd is about 3 L/kg, indicating extensive tissue distribution.
Transdermal: ~70% (relative to IV). Oral: <10% (extensive first-pass metabolism).
Transdermal: approximately 70-80% of the dose reaches systemic circulation.
No dose adjustment needed for any degree of renal impairment.
No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (Cr Cl <30 m L/min) may have increased risk of adverse effects; monitor closely.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh Class C: Avoid use or use minimal effective dose (e.g., 0.2 mg/h) with close monitoring.
No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Safety and efficacy not established in pediatric patients; no standard dosing guidelines.
Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Start at low end of dosing range (0.2 mg/h), titrate slowly, monitor for hypotension and dizziness. Increased sensitivity due to age-related vascular changes; may require extended nitrate-free interval (e.g., 12-14 hours).
Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
Hypotension, especially in hypovolemic patients; tolerance with chronic use; paradoxical bradycardia and increased angina; exacerbate hypertrophic cardiomyopathy; avoid abrupt discontinuation.
Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Concomitant use with PDE-5 inhibitors; severe anemia; increased intracranial pressure; hypersensitivity to nitroglycerin; acute circulatory failure; constrictive pericarditis; pericardial tamponade.
Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.
Avoid alcohol, as it can enhance hypotensive effects. No specific food restrictions, but high-fat meals may delay absorption of nitroglycerin if administered orally; transdermal route is less affected.
Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible fetal bradycardia, hypotension, and reduced placental perfusion; avoid near term due to risk of maternal hypotension and fetal distress.
Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for hypotension or methemoglobinemia; consider pump and discard if high doses used.
Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
No specific dose adjustments recommended; however, increased plasma volume may reduce drug concentrations; titrate to effect, avoid hypotension to maintain placental perfusion.
No specific dose adjustments recommended, but use lowest effective dose due to potential for hypotension and decreased placental perfusion.
NITRO-DUR (nitroglycerin) transdermal patch is used for angina prophylaxis, not acute attacks. Apply to hairless area, avoid chest if possible to prevent interference with defibrillation. Rotate sites daily to prevent tolerance; remove patch for 10-12 hours daily to maintain nitrate-free interval. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension. Monitor for hypotension, reflex tachycardia, headache.
MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia.
Apply patch once daily to clean, dry, hairless skin on upper arm, chest, or back.,Remove old patch before applying new one.,Keep patch on for 12-14 hours then remove for 10-12 hours to prevent tolerance.,Do not use during acute angina attack; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this patch.,Common side effects: headache, dizziness, flushing. Report severe headache or fainting.,Do not stop abruptly; may cause rebound angina.
Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily.,Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning.,Do not use for acute angina; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension.,Headache may occur; use acetaminophen or reduce dose; do not stop abruptly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-DUR vs MINITRAN, answered by our medical review team.
NITRO-DUR is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.. MINITRAN is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-DUR and MINITRAN depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-DUR is: Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.. The standard adult dose of MINITRAN is: Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-DUR and MINITRAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-DUR is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible . MINITRAN is classified as Category C. Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.